Latest Insider Transactions at Oncternal Therapeutics, Inc. (ONCT)
This section provides a real-time view of insider transactions for Oncternal Therapeutics, Inc. (ONCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oncternal Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oncternal Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 08
2024
|
Robert James Wills |
BUY
Open market or private purchase
|
Direct |
3,086
+23.58%
|
$24,688
$8.96 P/Share
|
|
Mar 28
2024
|
Robert James Wills |
BUY
Open market or private purchase
|
Direct |
6,914
+50.0%
|
$55,312
$8.48 P/Share
|
|
Feb 23
2024
|
Robert James Wills |
SELL
Open market or private sale
|
Direct |
980
-100.0%
|
$8,820
$9.04 P/Share
|
|
Feb 23
2024
|
David F Hale |
BUY
Open market or private purchase
|
Indirect |
266
+0.89%
|
$2,394
$9.04 P/Share
|
|
Feb 23
2024
|
David F Hale |
BUY
Open market or private purchase
|
Direct |
714
+50.0%
|
$6,426
$9.04 P/Share
|
|
Jan 03
2024
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,485
-22.53%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,955
-10.32%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Chase C. Leavitt General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
11,838
-12.26%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Richard G Vincent Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,868
-5.92%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Salim Yazji Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,742
-13.31%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Rajesh Krishnan CTO/CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,838
-21.19%
|
$0
$0.5 P/Share
|
|
Jul 03
2023
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,007
-16.75%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
47,992
-8.85%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Rajesh Krishnan CTO/CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,897
-16.32%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Salim Yazji Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,299
-9.9%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Richard G Vincent Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,069
-4.51%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Chase C. Leavitt General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
10,305
-9.64%
|
$0
$0.36 P/Share
|
|
Jun 14
2023
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+3.07%
|
$0
$0.36 P/Share
|
|
Jun 12
2023
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+21.42%
|
$0
$0.35 P/Share
|
|
Apr 14
2023
|
James B Breitmeyer Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
50,000
+10.43%
|
$0
$0.3 P/Share
|
|
Apr 14
2023
|
Salim Yazji Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+2.95%
|
$0
$0.3 P/Share
|
|
Apr 13
2023
|
James B Breitmeyer Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
100,000
+40.56%
|
$0
$0.29 P/Share
|
|
Apr 13
2023
|
Salim Yazji Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+5.89%
|
$0
$0.28 P/Share
|
|
Apr 13
2023
|
Richard G Vincent Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+16.05%
|
$0
$0.3 P/Share
|
|
Apr 13
2023
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Open market or private purchase
|
Direct |
10,000
+8.55%
|
$0
$0.29 P/Share
|
|
Apr 12
2023
|
Salim Yazji Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+6.26%
|
$0
$0.28 P/Share
|
|
Apr 12
2023
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Open market or private purchase
|
Direct |
15,000
+13.4%
|
$0
$0.29 P/Share
|
|
Jan 03
2023
|
Richard G Vincent Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,428
-3.37%
|
$4,428
$1.02 P/Share
|
|
Jan 03
2023
|
Salim Yazji Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,961
-6.66%
|
$9,961
$1.02 P/Share
|
|
Jan 03
2023
|
Gunnar F. Kaufmann Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,266
-8.58%
|
$6,266
$1.02 P/Share
|
|
Jan 03
2023
|
Chase C. Leavitt General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
6,091
-6.92%
|
$6,091
$1.02 P/Share
|
|
Jan 03
2023
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
1,325
-5.25%
|
$1,325
$1.02 P/Share
|
|
Jan 03
2023
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,793
-4.88%
|
$27,793
$1.02 P/Share
|
|
Jan 03
2023
|
Rajesh Krishnan CTO/CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,238
-8.55%
|
$6,238
$1.02 P/Share
|
|
Jul 28
2022
|
Richard G Vincent Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,125
+24.73%
|
-
|
|
Jul 28
2022
|
Salim Yazji Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+35.54%
|
-
|
|
Jul 28
2022
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
43,125
+32.89%
|
-
|
|
Jul 28
2022
|
Rajesh Krishnan CTO/CSO |
BUY
Grant, award, or other acquisition
|
Direct |
43,125
+37.14%
|
-
|
|
Jul 28
2022
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,125
+37.14%
|
-
|
|
Jul 28
2022
|
James B Breitmeyer Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
18,750
+42.62%
|
-
|
|
Jul 28
2022
|
James B Breitmeyer Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,625
+24.57%
|
-
|
|
Mar 28
2022
|
Richard G Vincent Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+2.76%
|
$2,500
$1.4 P/Share
|
|
Mar 25
2022
|
Richard G Vincent Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,497
+0.95%
|
$2,497
$1.47 P/Share
|
|
Mar 24
2022
|
Richard G Vincent Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3
+0.0%
|
$3
$1.45 P/Share
|
|
Jan 28
2022
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Open market or private purchase
|
Direct |
5,000
+10.03%
|
$5,000
$1.63 P/Share
|
|
Jan 28
2022
|
Richard G Vincent Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+2.92%
|
$2,500
$1.65 P/Share
|
|
Jan 27
2022
|
James B Breitmeyer Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
25,000
+34.94%
|
$25,000
$1.68 P/Share
|
|
Jan 27
2022
|
Salim Yazji Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+12.96%
|
$10,000
$1.69 P/Share
|
|
Jan 27
2022
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Open market or private purchase
|
Direct |
8,500
+17.57%
|
$8,500
$1.78 P/Share
|
|
Jan 27
2022
|
Richard G Vincent Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+6.02%
|
$10,000
$1.75 P/Share
|